223#Background:Apalutamide plus ADT (APA) demonstrated significantly improved overall survival (OS) compared to placebo plus ADT (PBO) for patients with mHSPC in the TITAN study (HR, 0.65; 95% CI, 0.53 to 0.79;P< .0001). At the time of final analysis, the median OS was not reached ...
WILMINGTON, Del.--(BUSINESS WIRE)--Sep. 9, 2024-- Detailed results from the TROPION-Lung01 Phase III trial showed a clinically meaningful trend toward improving overall survival (OS) with datopotamab deruxtecan (Dato-DXd) compared to docetaxel, the current standard of care chemotherapy,...
BLINATUMOMAB FOR MINIMAL RESIDUAL DISEASE (MRD) IN ADULTS WITH BCELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCPALL): MEDIAN OVERALL SURVIVAL (OS) NOT REACHED AT 5 YEARS FOR COMPLETE MRD RESPONDERS: S1619 来自 ResearchGate 喜欢 0 阅读量: 37 作者:...
It was not until 2007 that a systemic therapy sequencing approach demonstrated an overall survival (OS) benefit for patients with advanced HCC. Now, NEXAVAR followed by STIVARGA has shown a significant clinical benefit in OS, progression-free survival (PFS), and time to progression (TTP). Case...
A strong and clinically meaningful overall survival (OS) trend was observed at the interim analysis, with a 43% reduction in the risk of death (HR: 0.57 [95% CI: 0.40-0.80], p-value=0.00049), which has not yet reached the interim criteria...
with particularly encouraging results seen in those with exon 19 deletion (Del19)-positive disease (median time on treatment 30.3 months) and Asian patients (median time on treatment 46.7 months). Additionally, the 2 year and 2.5 year overall survival (OS) rates were 78.9% and 68.8%, respecti...
where L ˆ was the survival estimate and V ˆ is the standard error of L ˆ : V ˆ = L ˆ 2 ∑ t i ≤ t d i N i ( N i − d i ) . For each population, we calculated an overall MLE estimate that is based on the entire studbook dataset, including males, female...
with particularly encouraging results seen in those with exon 19 deletion (Del19)-positive disease (median time on treatment 30.3 months) and Asian patients (median time on treatment 46.7 months). Additionally, the 2 year and 2.5 year overall survival (OS) rates were 78.9% and 68.8%, respecti...
This is one of the strongest possible builds. But its not too newbie friendly! if are not good...
whereLˆwas the survival estimate andVˆis the standard error ofLˆ: Vˆ=Lˆ2∑ti≤tdiNi(Ni−di). For each population, we calculated an overall MLE estimate that is based on the entire studbook dataset, including males, females, and any individuals of unknown sex. We also esti...